AEP Vaccine and Immunization Calendar 2026 |AEP Vaccine Advisory Committee

AEP 2026 Vaccination and Vaccination Schedule

January 1, 2026

The Advisory Committee for Vaccination and Immunization of the Spanish Association of Pediatrics (CAV-AEP) updates its recommendations on vaccination in 2026 with the publication of its Vaccination and Immunization Calendar (available on January 5).

For more comprehensive information about this year's recommendations and their scientific basis, we recommend that you read the following document: AEP Vaccination and Immunization Calendar.2026 Reasons and Basis for Recommendations.

These recommendations are aimed at pediatricians, family doctors, nursing staff, gynecologists, midwives, relatives of children and generally anyone interested in up-to-date information on childhood vaccinations.

CAV-AEP reaffirms its goal of promoting the achievement of a uniform vaccination and immunization schedule, in order to maintain the principle of equity in preventing disease and providing health to the population.In the same way, the Committee believes that the joint effort of all health and political actors is necessary to decide on the vaccination and vaccination schedule for Spanish children and adolescents and offers its cooperation to achieve this reasonable goal, and in this sense we congratulate ourselves because the Ministry of Health has agreed on the "Common Schedule for Interpos for Life" approved by the STNS - Interpos Council.2019 and repeated in the following years, which also included some requests from the Spanish Association of Pediatrics (AEP), such as the inclusion of vaccination against pneumococci and chicken pox, and reducing the age for the administration of the human papillomavirus vaccine to 12 years, as well as revalcinesac 2 for 12 years. 2019, the quadrivalent vaccine against meningococcus in youth up to 18 years; 2021.Universal vaccination against SARS-CoV-2 for children and adults aged 5 to 18 years, and extension of this vaccine to risk groups 6 to 59 months in 2022.In 2023, the meningococcal B vaccine was introduced for children, the vaccine against influenza from 6 to 59 months, and the vaccine against HPV for children from 12 years, and the recommendation for vaccination against SARS-CoV-2 remained only for risk groups above 6 months.In addition, in the middle of 2023, the monoclonal antibody against respiratory syncytial virus (RSV), nersimab, was included in almost all of Spain for children under 6 months of age and up to 23 months of risk groups, as recommended by the AEP in January 2023, as the first international scientific community to do so in 2023.Finally, a vaccine is recommended in children, which is fully included in all CC.AA.In 2025, the ACWY meningococcal vaccine will be introduced to children between 4 and 12 months of age, as the AEP recommended in previous years.This funding makes the Spanish calendar the most complete in the world.

However, some requests remain, such as vaccinating against pertussis (Tdpa) for adolescents (Already in place in Asturias, Andalusia, Canary Islands, Catalonia and Madrid), reducing the age of administration to 10-12 years in 2025, lowering the second dose of SRPV to 2 years, offering anti-coccal vaccination for adolescents, and hepatitis A vaccination as a single dose within 12-15 months.Pending.Rescue them later.It is therefore considered advisable to make a joint economic effort of the CC.AA. and the Ministry of Education to finance a complete systematic calendar for children living in Spain, as was done in 2023, 2024 and 2025, using the five vaccines and monoclonal antibodies mentioned above.

HIGHLIGHTS IN CALENDAR 2026

At the beginning of each section, the key performance points of each vaccine are discussed.Changes from previous years have been retained, as the vaccine table has been ranked by age of use, with a renewed emphasis on vaccines not yet included in the CC.AA calendar:

- The systematic table maintains the non-discrimination between funded and unfunded because AEP considers that all are systematic immunizations that must be applied to all children, adolescents and pregnant women.

- Vaccination schedule against diphtheria, tetanus, pertussis, Haemophilus influenzae type B, polio, hexavalent vaccines carrying hepatitis B, with 2 + 1 schedule (2, 4, 11 months), DTP under 6 years.(DTPa-VPI), although TPA + VPI.

- As per the recommendation of standard-mass vaccine (DDPA), continue to urge, taking into account the limited period of immunity against pertussis, and then a second dose of TDPA is given 10-10 years later.

- maintain a 2 + 1 pneumococcal vaccination schedule with PCV15 (2, 4 and 11 months) or maintain a 3 + 1 schedule (2, 4, 6 and 11 months) with PCV20);

- Recommendation of rotavirus vaccine in children on a systematic schedule.

- Recommendation of the vaccine against meningococcal B as systematic in infants, in a 2+1 regime starting from two months;It is recommended that 4CMenB be given together with all vaccines in childhood vaccination schedules.Meningococcal B vaccination with either vaccine in unvaccinated adolescents with 2 doses and also booster vaccination with 1 dose of 4CMenB (meningococcal B vaccines are not interchangeable) in those adolescents who received this childhood vaccine.For the rest of the ages, the recommendation is individual protection.

- Influenza vaccine for all children from six months to 17 years, to protect them individually and to avoid catching other adults.And this means vaccination of risk groups and living with caregivers from 6 months of age.Best intranasal vaccine from 2 years.

- Renewal of the vaccination program against meningococci A, C, W and Y, with a plan (1+1+1) one dose at 4 months, another at 12 months and another at 12-13 years old, gradually saving those who are not vaccinated MenACWY up to 18 years old.For the rest of the age, the advice is personal protection.

- Maintain MMR and chickenpox vaccination schedule with 2 doses, recommend tetra viral vaccine (MRPV) for second dose, lower age for second dose to 2 years.

- Vaccination against SARS-CoV-2 (strain LP8.1 and if not available with substrain KP.2) for all children and adolescents at risk from 6 months of age.Vaccination with these new vaccines is also recommended as individual protection for all children and adolescents who wish to do so.

- Human papillomavirus vaccination is recommended for boys and girls aged 10 to 12 years, as the burden of neoplastic disease in boys due to this virus is also important.Choose HPV9 instead of HPV2 and receive funding up to age 18 for both men and women with a single dose up to age 25.

- Maintain the recommendation for the use of nirsevimab (monoclonal antibody against RSV) in infants less than 6 months to 2 years of age in risk groups of the disease (in premature infants less than 35 weeks to 12 months of age).

- The possibility to interactively consult the 2 usual tables (systemic and risk groups), where if we click on the vaccine we get the recommendation that appears in the base table of each table.

New this year:

- La vacunación frente a la hepatitis A en dosis única a los 12-15 meses con rescate con una dosis a niños y adolescentes sanos no vacunados con anterioridad.

- Create relief points in a systematic calendar.

- We have added a new table that connects different chronic patients with the vaccines they need to receive.

Other facts are:

- For vaccinations not yet included in the free program, request new forms of financing to make it easier for Spanish families to purchase them.

- Request to create a National Immunization Committee in which not only public health technicians of the Ministry and Central Committee, but also scientific societies and patients participate, as recommended by the World Health Organization (WHO).

AEP 2026 calendar table

The vaccination and immunization calendar, developed for childhood, youth and pregnancy, indicates the age at which vaccinations and immunity are administered, which is the one that all children in Spain should receive universally.

If immunization is not administered within the specified period, the recommendations for vaccination with an accelerated or rescue regimen should be followed (see below).

It is recommended to consult the vaccination and immunization schedule of the community or autonomous city itself.Side effects should be reported to health authorities.

(1) Vaccine against hepatitis B (HB).- Three doses at 2, 4 and 11 months of age, in the form of a hexavalent vaccine.Unvaccinated children and adolescents will receive 3 doses of a single component vaccine at 0, 1, and 6 months of age.

(2) Diphtheria, tetanus and pertussis vaccine (DTPa/Tdpa).– Five doses: 2-dose primary vaccination (at 2 and 4 months) and booster vaccination with DTPa-HB-Hib-VPI vaccine (hexavalent) at 11 months (3rd dose);Standard load preparation (DTPa-VPI) at 6 years of age (dose 4), preferably against low antigen load of diphtheria and pertussis (Tdpa-VPI), and Tdpa at 10-12 years of age (dose 5).Tdpa can be used at a 6-year dose since a new dose is not administered in cases previously vaccinated with a 3+1 vaccination program (2, 4, 6 and 18 months).Polio vaccination is mandatory.27-36.between gestational weeks, preferably 27-28.Tdpa is recommended in every pregnancy between 12 and 25 weeks of gestation.In possible cases, after a high-resolution ultrasound examination, premature birth can be made starting from the 20th week.

(3) Inactivated poliomyelitis vaccine (IPV).- Four doses: primary vaccination with 2 doses, boosters at 2nd and 4th months and 11th month (with hexavalent) and 6th year (with DTPa-VPI or Tdpa-VPI).In cases where previously vaccinated according to the 3+1 schedule (2, 4, 6 and 18 months), additional doses are not required.Vaccination schedules for children from countries where OPV is used or countries with a mixed OPV/OPV schedule can be found in our online immunization guide.

(4) Haemophilus influenzae type b (Hib) conjugate vaccine.- Three doses: primary vaccination at 2 and 4 months and a hexavalent booster at 11 months.

(5) Pneumococcal conjugate vaccine (PCV).Three or four doses: 2+1 schedule with PCV15 (2, 4 and 11 months) or 3+1 schedule (2, 4, 6 and 11 months) with PCV20.

(6) Rotavirus (RV) vaccine - two or three doses: at 2 and 3-4 months with a monovalent vaccine, or at 2, 3, and 4 months or at 2, 3-4, and 5-6 months with a pentavalent vaccine to reduce the risk of infection. Although rare, the treatment regimen should be started at 6 to 12 weeks and should be continued at 24 weeks with the monovalent and atComplete with pentavalent at 33 weeks.The minimum interval between doses is 4 weeks.Both vaccines can be given in combination with other vaccines (except polio vaccine, which is not marketed in Spain).

(7) Meningococcal B (MenB) vaccine.- 4CMenB.3 doses: If at least 6 months have passed since the last dose of primary immunization, a booster dose starting at 2 months and at 2 months and 12 months, respectively.4CMenB is recommended to be given together with all vaccines in the childhood vaccination schedule. In adolescents, it is given systematically at 12 years of age for those who have not yet received the vaccine.For those who completed vaccination in childhood, there is a 4CMenB booster dose (does not support interchangeability of meningococcal B vaccine). For the remaining age groups, rescue with two previously unvaccinated vaccines (4CMenB or MenB-fHbp) is possible, and the minimum age of authorization for each vaccine should be adhered to.

(8) Meningococcal ACWY (MenACWY) conjugate vaccine.- One dose of MenACWY-TT conjugate vaccine at 4 months of age if under an autonomous community-sponsored program;Otherwise, the rules defined in the MenACWY-TT data sheet (Pfizer) will be followed;Booster dose for 12-month MenACWY-TT (Pfizer or Sanofi).MenACWY dose in adolescence (11-13 years), recommended rescue dose up to 18 years in unvaccinated patients.In CC.AA.If the MenACWY vaccine is not included in the routine schedule at 4 and 12 months, their community-sponsored MenC-TT should be administered if parents decide not to administer it.For the remaining ages, in previously unvaccinated subjects, rescue with any of the three vaccines, observing the minimum age allowed for each of them.

(9) flu vaccine .- It is recommended for all children between the ages of 6 months and 17 years, with inactive vaccines (some preparations can also be administered deep subcutaneous) or with diluted intragenal vaccines, the last of 2 years and ideal, as long as there are no contraindications.Do not use medicine once.The doses separated with 4 weeks are given if this is the first time you have been vaccinated, but if you received a dose in the previous season, in one more time is given a dose.The dose is 0.5 ml inwardly for the inactive and 0.1 mly in each nostril for diluted.you have not been vaccinated during pregnancy.

(10) Vaccine against SARS-CoV-2. One dose in each trimester of pregnancy.If previously vaccinated or if they have had an infection, at least 3 months after the event.Also indicated in the postpartum period, up to 6 months after giving birth if you have not been vaccinated during pregnancy.It can be given together with the flu vaccine or tdpa.

(11) Hepatitis A vaccine.- One dose between 12 and 15 months.Use a single dose to deliver the vaccine to healthy children and adolescents who have not been vaccinated before.

(12) Vaccine against measles, rubella and mumps (MMR).- Two doses of vaccine against measles, rubella and mumps (MMR).1st at 12 months and 2nd at 24 months.A second dose can be administered in the form of tetraviral vaccine (SRPV).In susceptible patients beyond the above-mentioned age, vaccination with 2 doses of MFR with an interval of at least one month is recommended.

(13) Chicken pox vaccination (Var).- Two doses: 1st at 15 months (also valid at 12 months) and 2 at 24 months.A 2nd dose can be administered in the form of a tetraviral vaccine (SRPV).For vulnerable patients outside the prime age group, vaccination with 2 doses of the single-component vaccine is recommended with an interval of at least 1 month, and 12 weeks is recommended for those under 13 years of age.

(14) Vaccine against human papillomavirus (HPV) .- Systematic vaccination against HPV at the age of 10-12 years with a single dose.It is recommended to use the HPV-9 vaccine with multiple genotypes.Funded rescue vaccination (one dose) until the age of 18, for girls and boys.Its co-administration with MenACWY, hepatitis A and B and Tdpa vaccines is possible.There is no data on chicken pox regarding the co-administration of the vaccine, although it does not cause problems.

(15) Immunization against respiratory syncytial virus (RSV).The RSVPreF vaccine is given between 24 and 36 weeks of gestation, preferably between 32 and 36 weeks of gestation. It will not be funded by Public Health in the 2025-2026 season, although it is available in the community.Nirsevimab (anti-RSV antibody) is recommended for all newborns during the RSV season (October to March) and for infants under six months of age (born April to September) at the beginning of the season.Neonates whose mothers received RSVPreF during pregnancy should receive nirsevimab before hospital discharge.should be taken

Vaccination of vulnerable groups

(1) Vaccine against hepatitis B (HB).- Infants of HBsAg-positive mothers will receive a dose of the vaccine and another dose of hyperimmune immunoglobulin against hepatitis B (HBHI) (0.5 ml) within the first 12 hours of life.If the mother's serology is unknown, the vaccine should be given in the first 12 hours and the serology done, and if positive, 0.5 ml of IGHB should be given, especially in the first 72 hours of life.Newborns are vaccinated according to the standard practice in the first year, with four doses against HB.There are other risk groups as well.

(2) Haemophilus influenzae type b (Hib) vaccine - a single dose in persons older than 59 months of age before vaccination according to risk groups: anatomic or functional asplenia;lack of complementary factors;eculizumab or ralizumab or sotelimab and HIV disease;History of HIV disease;at 59 months with no vaccination or an incomplete schedule;Update CAV-AEP vaccines on a rush or rescue schedule.

(3) Pneumococcal vaccine.- If VNC20 is available, it should be preferred over 23-valent polysaccharide vaccine (VNP23) in vaccinees previously vaccinated with VNC13 or VNC15.In the case of a complete VNC20 regimen (primary vaccination and booster), or a single dose of VNC20 to complete a regimen started with VNC13 or VNC15, there is no need to administer VNP23 or multiple doses of VNC20.vaccine (VNC13 or VNC15), but only if VNC20 is not available.The minimum interval between the last dose of VNC, whether to administer VNC20 or VNP23 in those previously vaccinated with VNC13 or VNC15, is 8 weeks.

(4) Vaccine against meningococcus B (MenB).- 4CMenB.It is recommended at any age in the risk group of one year (if less than one year, they will receive the usual systematic course): anatomical or functional asplenia, deficiency of complement factors, treatment with eculizumab or ravulizumab or sutimlimab, recipients of hematopoietic stem cell transplants, HIV infection, previous episodes of IMD and contact cases of serogroup B due to several serogroup B. serogroup. in the context of epidemic outbreaks. Furthermore, they must receive, except those under two years of age and a history of meningococcal diseaseinvasive (IMD), MenB dose one year after completion of primary immunization and then every 5 years.In the case of IMD outbreaks due to serogroup B, patients with risk factors should receive a booster dose if at least one year has passed since the completion of the primary vaccination series.From the age of 10, one of the two vaccines can be used, considering that they are not interchangeable.

(5) Meningococcal ACWY (MenACWY) conjugate vaccine: For those at risk of IMD; Serogroups A, C, W or Y in the context of an epidemic outbreak.Primary vaccination at any age with 2 doses at least two months apart.If the risk situation persists, it is recommended that children under 7 receive a dose every 3 years and children over this age every 5 years.

Travelers to Mecca for religious reasons and in the so-called African meningitis belt during the dry season should also take MenACWY.

(6) Influenza vaccination.- It is recommended for all risk groups and couples from 6 months of age.For advice on risk groups for this vaccine, you can access the CAV-AEP Recommendation Document for the 2025-2026 season.

(7) Vaccine against SARS-COV-2.- According to the recommendations of the Spanish Public Health Commission for vaccination against Covid-19 for the 2025-2026 season, a vaccination in 6-month-olds with high or high risk conditions is set out or receiving immunity treatment or living with people at risk, as well as in long-term care centers or more.Foundation of institutions.The vaccines to be used are monofralent with the LP8.1 stress and if not available with KP.2: Comirnety (in form 3 mcg [children 6 months to 4], 10 mcg [5 to 11 years] or 30 mcg [12 and oldFor 2 5 mcg doses of 0.0 ml / 0.0 ml for 2 5 mcg of multiple doses of 0.0 ml for 0.0 ml of doses of 0.0 ml.Month to 11 years] or 5 doses of 0.5 ml / 50 mcg [11 years and oldimmunity, where they will get an extra dose of 3 months without a period of vaccine in the past.Infection: people aged 5 or over, one dose;Children aged 6 months to 4, 3 doses (with a break of 3 weeks between the first and second weeks and 8 weeks between the second and third) Comirnety, 3 mcg or 2 doses of Spikevax (0.25 ml / 25 mcg) on ​​days 0 and 28. For those children between 6 months and 4 years with one incomplete procedure, the new regime will be completed with one previous blank.vaccines.Seasonal dose groups are at risk: one dose, regardless of previous doses, in vaccinated or re -infected patients, with a break of 3 months after vaccination or disease.Risk groups can be consulted in the recommendations of the Ministry of Health and in the online manual for CAV-AEP immunization.

(8) Vaccination against hepatitis A. - You can talk to risk groups before and after vaccination in our guide.Infants aged 6-11 months who travel to risk areas receive the vaccine, but it is not considered an official dose, so the series of vaccines (2 doses) is not considered and should be started again from 12 months ago.

(9) Human papillomavirus (HPV) vaccination.- It is indicated from the age of 9 years, always with 3 doses in case of immunosuppression.Check out the vaccination guide for other risk groups.

(10) Vaccination against respiratory syncytial virus (RSV) .- The annual use of nirsevimab is recommended for children under two years of age with underlying diseases that increase the risk of severe RSV infection, preferably before the normal start of the RSV season (October).In the second season and whenever their weight is 10 kg or more, the dose is 200 mg, with 2 injections of 100 mg;If their weight is less than 10 kg, 100 mg is used.Children born prematurely under 35 weeks (including those with a gestational age of less than 29 weeks) will receive another dose until they reach the age of 12 months (if they received a new dose in the previous season, they can receive a new dose of 100 mg at the beginning of the 2025-2026 season (200 mg if they have not reached 10 kg or more than 10 months or more than 12 months).

Immunization for children and adolescents with chronic diseases

Rescue or rapid vaccination

- Recommended No. per Chitovo Tas, depending on age

- 6 MONTHS and 6 EVENT OR ACCELERATED BETWEEN 4 YEARS

- RESCUE OR ACCELERATED VACCINATION BETWEEN 7 AND 18 YEARS OLD

NO. DOSAGE ACCORDING TO AGE

This table shows the number of doses needed, according to age, for children and adolescents whose vaccination schedule has not yet started, is incomplete, or who started vaccination later.It is not necessary to restart the vaccination schedule if previous doses have been given, respecting the minimum interval between doses and the minimum age of administration, but to complete it even if the recommended interval between doses has been exceeded ("Dose given, dose important").

(1) Vaccine against diphtheria, tetanus and pertussis (DTPa) - with the standard 2+1 schedule (2, 4 and 11 months), the fourth dose will be given at 6 years of age (DTPa-VPI, preferred over Tdpa-VPI), if at least 6 months have passed since the previous dose and after 4 years of life.With a 3+1 schedule (2, 4, 6, and 12–18 months), a fifth dose of DTPa or Tdpa is not necessary if the fourth dose of DTPa is administered 4 or more years later.Tdpa, with low antigenic load diphtheria and pertussis components, is authorized from age 4 years and Tdpa-VPI from age 3 years.DTPa-VPI is available for 2 months (Tetraxim) and 16 months (Infanrix-IPV) to 13 years.AEMPS has approved the use of two existing preparations of DTPa-VPI (Tetraxim, Infanrix-IPV) for primary vaccination from 2 months and booster doses up to 13 years.

(2) Vaccination against low antigenic load tetanus and low antigenic load diphtheria/pertussis (Td/Tdpa).- The current standard regimen consists of 3 doses at any age;adults must receive 2 booster doses to complete the 5 doses required to be considered immune to tetanus.To renew the first primary and booster vaccine or an incomplete schedule, give DTPa vaccine in the hexavalent form at age 6 years.(DTPa-HB-Hib-VPI, approved up to 6 years of age) or with inactive polio (DTPa-VPI, approved up to 13 years of age inclusive).From the age of 7, DTPa-VPI (up to 13 years of age) or Tdpa can be used for the first 3 doses, and Tdpa or Td can be used to complete the 5 doses.

(3) Inactivated polio vaccination (IPV).- Children under 4 years of age should receive or have received 3 or 4 doses of trivalent polio vaccine (VPOt given before April 2016, or IPV) according to the schedule started: 4 doses in the schedule, 3 + 2 schedule, if it starts in 3 + 2 months. 2 + 1, the last dose always starts at 11 monthsof age, but it should be considered that the second dose needs a 4th dose in the form of DTPa-VPI at the age of 6 years, if the 3rd dose of polio was not given at the age of 4 years, they do not need more doses.Children from the age of four to teenagers must receive or receive at least 3 doses of the trivalent vaccine;the 4th dose only if the 3rd dose is given before the age of 4 years.If necessary, in the case of 4 and 5 years, it should be given as DTPa-VPI at 6 years.

People from countries using oral poliomyelitis who received a bivalent OPV-only regimen (given after April 2016) should receive the above age-appropriate doses of OPV, with the recommended dosing intervals.If they received trivalent VPO or VPI or mixed with VPI and VPO, doses of trivalent vaccines will be included in the total number of doses at the recommended age and will be supplemented with VPI if necessary;If 2 doses of VPI are required, the minimum interval between them is 6 months.

(4) Immunization against Haemophilus influenzae type b (Hib) - Number of doses according to age of onset: 3 in children under 12 months;2 between 12-14 months;1 between 15 months and 5 years.

(5) Pneumococcus vaccine conjugate (PCV).- Number dosed according to age of attack: 3 in children under 12 months with PCV15 and 4 with PCV20;2 between 12-23 months;between 24 months and 5 years: 1 VNC containing the total number of serotypes (doses at risk of 2 groups);between 6 and 17 years, only in risk groups, 1 dose of VNC with the total number of serotypes.VNC10 is allowed up to 5 years of age, VNC13, VNC15 and VNC20 up to adulthood, without a limit.

(6) Rotavirus vaccine (RV).- Two doses of monovalent vaccine or three doses of pentavalent vaccine.To minimize the risk, although rare, of intestinal intussusception, it is recommended to start the regimen between 6 and 12 weeks of age and should end before 24 weeks of age with monovalent and 33 weeks with pentavalent.

(7) Vaccine against meningococcal B (MenB).- Number dosed according to age of access: 3 between 2 to 23 months (4CMenB);2 between 2 to 50 years (4CMenB);2 between 10 and 65 years (MenB-FHBP).

(8) Meningococcal conjugate vaccine ACWY (MenACWY).- MenACWY, one dose is recommended at 4 months, the second at 12 months and the last vaccine at 11-13 years of age.Save with one dose for unvaccinated 13-18 year olds.A dose of MenC or MenACWY should always be given at 12 months of age instead of 12 months of age when this booster dose should always be given.If given by mistake at 11, it may be accepted as valid.In CC.If the AA MenACWY vaccine is not included in the systematic calendar at 4 and 12 months, if parents choose not to give it, they should use the MenC-TT funded by their community;if they decide to change, the schedule will be as indicated in the technical sheet: if the vaccination starts before the 6th month, you get 2 doses, there should be an interval of at least 8 weeks between them;if vaccination starts after 6 months: one dose.After primary vaccination of infants aged 6 weeks to less than 12 months, a booster dose at 12 months of age should be given at least 2 months after the last dose.For the remaining ages, revaccination in those who have not been previously vaccinated or have an incomplete schedule.For those first vaccinated at age 10 or older, MenACWY 1 dose;if he is before 10 years of age, he needs 2 doses, one after 10 years of age.

(9) Influenza vaccine.- Systematic indication for all children from 6 months to 17 years, and from 6 months in risk groups and their roommates and contacts.If you are under 9 years old and belong to a risk group, in the first season you will receive 2 doses 4 weeks apart;If you received any dose in the previous season, one dose will be applied.In healthy children from 6 months and even if it is the first season, one dose.If you are 9 years or older, you will only need one dose per season, even if you belong to a risk group.Intranasal is preferable from 2 years of age, if there are no contraindications.

(10) Vaccination against SARS-CoV-2.- According to the recommendations of the Spanish Health Council for vaccination against COVID-19 for the period 2025-2026, vaccination is indicated for people from six months of age with advanced or very dangerous conditions or receiving immunotherapy or living with people at risk, and for disabled people in the company that grows in 5 years. base.Vaccines to be used are monovalent containing type LP8.1, and if not available for KP.2: Comirnaty (with presentations of 3 mcg (children from 6 months to 4 years), 10 mcg (from 5 to 11 years) or 30 mcg [12 years and more for the presentation of 2.51 0.5 ml. [children from 6 months to 11 years] or 5 doses of 0.5 ml /50 mcg [age 11 years and older]).Primary vaccination for people older than six months who have been infected: one dose, with an interval of at least 3 months after infection, unless they belong to groups with a high level of immunity, in which case they will receive an additional dose with an interval of three months between doses.Primary vaccination without a history of infection: persons aged 5 years or older, one dose;children between 6 months and 4 years, 3 doses (with an interval of 3 weeks between the first and second, and 8 weeks between the second and third) of Comirnaty, 3 mcg, or 2 doses of Spikevax (0.25 ml / 25 mcg) on ​​days 0 and 28. In children between 6 months and 4 years of immunization will be completed with a new vaccine.partial immunity.Period rate in groups of risk: one dose, regardless of the number of doses previously received, for those who have already received vaccination or passed infection, with an interval of 3 months for vaccination or disease.Risk groups can be consulted in the recommendations of the Ministry of Health and in the online Immunization Guide of CAV-AEP.

(11) Hepatitis A vaccine. - In healthy children, one dose in 12-15 months.Rescue vaccination with one dose for healthy children and adolescents who have not been previously vaccinated.In high-risk groups, there are always 2 doses separated by 6 months.

(12) Measles, rubella and mumps vaccine (MMR) .- the first dose at 12 months. The second dose at 2 years with SRPV, although the administration of SRP and Var is accepted separately in the vaccination meeting at this age.Above this age, in people who have not been vaccinated, two doses at an interval of at least 4 weeks, preferably with a tetraviral vaccine if the chicken pox vaccine must be done.

(13) Vaccine against chicken pox (VAR) .- First dose at 15 months of age (also acceptable at 12 months).DDoS at 2 years of age with SRPV, although using SRP and Var separately in the same vaccination session is acceptable at this age.In unvaccinated persons above this age, two doses of Tetraviral, if the vaccination must also be vaccinated against measles, rubella and mumps.

(14) Vaccine against the human papilloma virus (HPV).- One dose at the age of 10-12 years, with HPV-9 vaccine.Extraction up to the age of 18 is not vaccinated in one dose, except for immunocompromised (3 doses with a schedule of 0, 2 and 6 months, at any age from 9 years).

Keep between 4 months and 6 years

This table shows the minimum age of the first dose of the indicated vaccine and the minimum interval between doses for children under 6 years of age with an unknown, incomplete or delayed starting schedule.According to the minimum interval between the previous dose and the minimum age of administration, the vaccination schedule should not be restarted if the previous dose has been administered, but rather completed even if the recommended interval between doses has been exceeded ("given dose, calculated dose").

(1) Vaccination against hepatitis B (HB).- In the standard 2+1 regimen (2, 4, 11 months), when the vaccine is injected into hexavalent preparations, the minimum interval between doses 1 and 2 is 8 weeks and the interval between doses 2 and 3 is 6 months.In the conventional 0, 1, 6 month regimen, the minimum interval between doses 1 and 2 is 4 weeks, 8 weeks between doses 2 and 3, 16 weeks between doses 1 and 3 and the third is not earlier than 6 months.If a newborn is given 1 dose of monocomponent vaccine, 3 more doses are used in hexavalent form according to the standard scheme (2, 4, 11 months).

(2) Diphtheria, Tetanus, and Pertussis (DTPa/Tdpa) vaccine.- In the standard 2+1 regimen (2, 4 and 11 months) with hexavalent vaccines, the minimum interval between the 1st and 2nd doses of DTP is 8 weeks, and between the 2nd and 3rd doses - 6 months;If the third dose was given at age 11 months or older and is separated from the second minimum dose by 4 months, it should be considered valid and does not need to be repeated, but the 4-day grace period provided for standard minimums cannot be applied to this reduced interval.In this regimen, if the 3rd dose was given after 4 years, the 4th dose would not be required, but in this case it should be noted that 5 doses are needed to effectively vaccinate adults against tetanus.

If the vaccination started with a 3+1 schedule (2, 4, 6 and 12-18 months), the minimum interval between the first and 2 and between 2 and 3 doses is 4 weeks and between 3 and 4 months is 6.If it is given at 4 or 12 months of age or older and is separated by 3 at least 4 months, it must be considered valid and need not be repeated, but the grace of the 4-thirty day for the smallest sign cannot be applied to this interval.According to this system, the 5th dose of Tdpa at age 6 is not necessary if the 4th dose of DTPa was given at age 4 or more, but two more doses will be required in the future for a total of 6 doses (see the corresponding section in the support calendar between 7 and 18 years).If not, the 5th dose will be given at 6 years as DTPa or Tdpa, as long as at least 6 months have passed since the previous dose.

DTPa, contained in a hexavalent preparation, can be administered up to 7 years of age following AEMPS approval in June 2019. DTPa-VPI can be administered up to 2 months (Tetraxim), 16 months (Infanrix-IPV) and 13 years.AEMPS has approved two preparations of DTPa-VPI (Tetraxim, Infanrix-IPV) for primary vaccination from 2 months of age and for booster vaccination up to 13 years of age.Regardless of age, if there are contraindications to the pertussis component.Use Td instead of DTPa or Tdpa.

(3) Inactive polio vaccine (IPV).- With the standard 2 + 1 method, the minimum time between the 1st and 2nd dose is 8 weeks and between the 2nd and 3rd dose 6 months;If this third dose has been given for 11 months or more and there is at least four months between the second dose, it is considered valid and does not need to be repeated, but the four-day grace period allowed for the minimum conditions will not be used in this shortened period.If the 3rd dose was given before 4 years, the 4th dose is needed, in the form of DTPa-VPI for 6 years, but if it was given after 4 years, no more doses are needed.If the schedule is 3 + 1 (months 2, 4, 6 and 12-18), the minimum time between the first 3 doses is 4 weeks, and between the 3rd and 4th 6 months, but if the 4 was given for 12 months or more and there is at least 4 months between the 3rd, this should not be considered important, but does not need to be shortened. can take advantage of the 4 day grace period allowedfor the minimum standard.With this method, the 6-year anti-polio dose according to the DTPa-VPI method is not necessary.

Those from countries that use the oral polio vaccine and who only receive bivalent OPV (which has been published since April 2016), must receive the dose of IPV that corresponds to their age (4 doses for children under 4 years, 3 doses for children between 4 and 6 years), with the minimum intervals recommended in the table.If you have received trivalent VPO or VPI, or mixed with VPI and VPO, the dose of trivalent vaccine is calculated for the total number of doses per year recommended, and completed with VPI if necessary;If it is necessary to administer 2 doses of VPI, the minimum time between them is 6 months.

(4) Conjugate vaccine against Haemophilus influenzae type b (Hib) - With the standard 2 + 1 method, the first two types of hexavalent vaccine will be given for at least 8 weeks and boosters from 11 months and 6 months away from the second.With the 3+1 cycle (months 2, 4, 6 and 12-18), the minimum time between the first 3 cycles is 4 weeks and between 3 and 4 is 6 months.If vaccination begins between 12 and 14 months, 2 doses are separated by eight weeks.If you start between 15 and 59 months, only one dose is needed.Immunization is not necessary for people over 5 years of age, except for vulnerable groups.

(5) Pneumococcus conjugate vaccine (PCV).- In the standard 2 + 1 (PCV15) regimen (2, 4, and 11 months), the minimum interval between the first 2 vaccinations is 8 weeks, and the third dose should always be administered from 11 months, with at least 8 weeks of separation days from 2. And the fourth is 8 weeks.The fourth dose is always administered from 11 months. If vaccination begins between 12 and 23 months, it will include 2 doses, separated by eight weeks.If the first dose is given at 24 months or more, only one dose is required in VNC with a high number of serotypes, except for those over 2 years old. Except for one risk where a single dose of VNC with the highest number of serotypes will be given, the 23-valent polysaccharide vaccine (VNP23) is indicated for those aged 2 years with an increased risk of pneumococcus infection.

(6) Rotavirus Vaccine (RV) - According to the preparation of the vaccine: monovalent, 2 doses and pentavalent, 3 doses;It is recommended to start the regimen between 6 and 12 weeks of age;the last dose must be given before 24 weeks of age with monovalent and 33 weeks with pentavalent.

(7) Vaccine against meningococcal B (MenB).- 4CMenB.If it starts at the age of 2 months, 2 doses at an interval of 8 weeks and one dose from the age of 12 months will be applied, with an interval of at least 6 months with the last primary.If it starts between 6 and 11 months, the 2 main doses will be separated by at least 8 weeks and the booster dose will be applied in the second year of life, at least, separated by at least 8 weeks from the last primary vaccination dose.At 12 and 23 months, the 2 main doses will be separated by at least 8 weeks and the booster dose will be administered 12 to 23 months after the last main vaccination dose.If applied between the ages of 2 and 50 years, vaccination consists of 2 doses with an interval of 4 weeks.For the rest of the age (except infants and adolescents who are systematically recommended at age 12), take it again in people who have not been vaccinated before or with an incomplete schedule.Indications for selection at any age in the risk group from 2 months of age: anatomical or functional asplenia, complement factor deficiency, treatment with eculizumab or revulizumab or sutimlimumab, recipient of hematopoietic stem cell transplant, HIV infection, previous IMD episode with respect to serogroup and BMD with respect to IMD group.An epidemic broke out.

(8) Meningococcal conjugate vaccine ACWY (MenACWY).- Starting from the 4th month, a dose of MenACWY-TT (Pfizer) is necessary if it is included in the systematic scheme, because otherwise the Pfizer MenACWY-TT technical sheet will be followed: if the vaccination is started before 6 months, they must receive 2 doses with a minimum interval of 8 weeks between them;if vaccination is started from 6 months: one dose;another MenACWY-TT (Pfizer or Sanofi) in the 2nd year of life, preferably at 12 months, and 1 dose of MenACWY-TT (Pfizer, Sanofi) or MenACWY-CRM (GSK) at 11-13 years.Rescue even with one dose in unvaccinated people between 13 and 18 years.Exceptionally, it may be accepted as valid if a MenC or MenACWY dose is mistakenly given at 11 months of age instead of 12 months, which is the age at which this booster dose should always be given.In CC.AA.if the MenACWY vaccine is not included in the 4th and 12th months in the systematic scheme, if it is not given in an unfunded way, it will be necessary to use the MenC-TT funded by your community.For the rest of life, re-uptake in subjects previously unvaccinated or with an incomplete schedule.

It is still recommended especially for children and adolescents who will live in countries where vaccination is indicated at this age, such as Canada, USA, Argentina, Brazil, Chile, Saudi Arabia, Australia, Andorra, Austria, Belgium, Cyprus, Slovakia, Greece, Ireland, Italy, Malta, Netherlands, Great Britain, Czech Republic, San Marino and Switzerland.For religious reasons, Mecca and during the dry season those traveling to the so-called African meningitis area must also receive MenACWY.For children older than 6 weeks, if they travel to countries with a high incidence of IMD due to the serogroups included in the vaccine, or where there are risk factors for IMD: anatomic or functional asplenia, deficiency of complement factors, treatment with eculizumab or ravulizumab or sutimlimab, infection of hematopoietic recipients with HIV stem cells, stem cells of IMD recipients.serogroup and contacts of the index case of IMD caused by serogroup A, W, or And in association with the outbreak.

(9) Influenza vaccine.—Routine administration in all children 6 months to 17 years of age and at risk from 6 months and in their household and contacts.If you are under 9 years old and in the risk group, in the first season you will receive 2 doses separated by 4 weeks;If you received a dose in the previous season, a dose will be administered.In healthy children from 6 months and even if it is the first season, a dose.If you're age 9 or older, you'll only need one dose per season.Suitable for internal use from 2 years of age.

(10) Vaccine against SARS-CoV-2.- According to the recommendations of the Spanish Health Commission for the period 2025-2026 for the vaccine against COVID-19, the vaccine is indicated from the age of 6 months to high-risk or high-risk people receiving immunosuppressive treatment or living with people at risk or in a nursing home or nursing home. Long-term basis.The vaccines to be used are monovalent vaccines with type LP8.1, and if they are not available with KP.2: Comirnaty (3 mcg [children 6 months to 4 years], 10 mcg [5 to 11 years] or 30 mcg [over 12 years] dose for 10.5 months and 2child 2chi more] up to years11] or 5 doses of 0.5 ml/50 mcg [11 years and older.The first and second, and 8 weeks between the second and third) Comirnaty, 3 mcg, or 2 doses of Spikevax (0.25 ml/25 mcg) on days 0 and 28. In children from 6 months to 4 years old with incomplete previous vaccination, the regimen is completed withone of the newer single-component vaccines.Time limit by risk groups: one dose, regardless of the number of doses obtained before, for those who have been vaccinated before or who have had an infection, vaccination or death within 3 months. Groups of vulnerable people can be consulted according to the recommendations of the Ministry of Health and in the CAV-AEP network guide of vaccines.

(11) Hepatitis A vaccine. For healthy children, one dose at the age of 12-15 months. Rescue vaccination with one dose for healthy children and teenagers who have not received vaccination before.If given between the ages of 6 and 11 months per visit, this dose is not included in the treatment from the age of 12 months onwards.In pre-exposure and post-exposure risk groups, always 2 doses every 6 months starting at 12 months.

(12) Measles, Rubella and Mumps (SRP) vaccine.- Two doses, the first at 12 months of age (a dose given from 11 months is considered valid under certain circumstances) and the second at 2 years of age in SRPV form, although application of SRP and Var is accepted, although vaccination is considered appropriate if 2 doses are given at least 4 weeks apart at 1 day of this age or at a different age (maybe) from 11 months.

(13) Varicella vaccine (Var).- Two doses, the first at the age of 15 months (also allowed from 12 months) and the second at the age of 2 years with SRPV, although the use of Var and SRP is allowed at this age (on the same day or at least 1 month apart).The minimum interval between two doses of Var is 4 weeks, although a 12-week interval is recommended for children under 13 years and 12 months, this is not considered valid and will not count towards the two-dose schedule.

Rescue begins within 7 to 18 hours

This chart shows the minimum age of dose 1 of the recommended vaccine and the interval between doses of the same vaccine for children from 7 years of age and adolescents who have not started, have not completed or who have started the last vaccine.The series of injections should not be restarted if the first dose was given, according to the minimum time between doses and the minimum age of the administration, but more completely, even if the recommended time between doses is greater ("Dose given, ratio").

(1) Hepatitis B (HB) vaccine.- In unvaccinated people above 7 years of age, 3 doses at 0, 1 and 6 months schedule.The third dose is given 8 weeks after the second dose, if at least 16 weeks have passed since the first dose, and preferably 6 months.

(2) Vaccine against tetanus, diphtheria and pertussis (Td/Tdpa/DTPa).- From the age of 7 years, the rescue regime of children or teenagers who have not been previously vaccinated or whose vaccination status is unknown, must ensure the receipt of 3 doses of the vaccine: 2 doses in 64 doses and an interval of 64 doses and one month.DTPa-VPI (up to and including 13 years of age), Tdpa or Td vaccines can be used.At least one of them, preferably the first with Tdpa or DTPa-VPI, if poliomyelitis is needed, and the others with Td or Tdpa or DTPa-VPI.Those who previously received one dose will need 2 doses with an interval of 6 months between them and always with a minimum interval of 4 weeks compared to the single administered dose.Those who previously received 2 doses should receive a third dose, with a minimum interval of 6 months from the last dose.in all cases, after the three doses mentioned have been completed, the 2 doses needed to complete the total series of 5 needed to complete lifetime tetanus vaccination should be scheduled, at minimum 1-year intervals, with Td (or Tdpa if not previously administered) or, if given 5 or more years apart, preferably with Tdpa to maintain perceptual protection.

Adolescents older than 7 years and younger than 14 years who received the 3+1 schedule (at 2, 4, 6, and 12-18 months) and who did not receive additional doses after that need two additional doses, preferably first with Tdpa (or DTPa-VPI), even if the second booster dose has been received. corresponds to age 14 years and provided that at leasta year has passed, although they receive a total of 6 doses of the vaccine containing the tetanus component.If they are 14 years of age or older and have received the 3+1 regimen, they also need 2 doses, at least one year apart.

Based on expert advice, it has been decided that if the child receives the 2+1 or 3+1 method with the age 6 dose as well, and mistakenly takes the last dose of Td or Tdpa starting at age 10, the age 14 to 16 dose is not appropriate.

The FDA has approved TdPA vaccines only for people over 7 years of age.The CDC does not recommend DTPA for people older than 6 years of age to avoid an increased risk of reactogenicity.

Pregnant teenagers should receive a dose of Tdpa with each pregnancy, regardless of whether a dose of Td or previous Tdpa was received, preferably between 27 and 32 weeks of pregnancy.

(3) Inactivated Polio Vaccine (IPV).- 3 doses are required for children aged 7 years and unvaccinated adolescents.It can be offered with schedules of 0, 1 and 2 months or 0, 1 and 6 months.If the first vaccinator received the 3rd dose before the age of 4 years, the 4th dose should be given.

Those from countries using oral polio who received a bivalent OPV-only regimen (administered after April 2016) must receive the 3 indicated age-appropriate doses of OPV at the minimum intervals recommended in the table. If they received trivalent VPOt or VPI or mixed with VPI and VPO, the trivalent vaccine doses will count towards the total of 3 recommended doses and will be supplemented with VPI if necessary;2 doses of VPI, there is a minimum interval of 6 months between them.

(4) Pneumococcal conjugate vaccine (PCV).- PCV13, PCV15 and PCV20 are allowed until the age of majority without age restrictions.All non-vaccine risk groups will receive 1 dose of VNC15 and 8 weeks later 1 dose of 23-valent polysaccharide vaccine (VNP23).If they receive PCV20, they will not need a dose of PCV23.Once they have received VNP23, they will be able to receive 1 affordable dose of VNC containing multiple serotypes at least 5 years apart (12 months in high-risk groups).High-risk groups will receive the 2nd and final dose of VNP23 5 years after the 1st dose when they received VNC15 because if they receive VNC20 they will not need it.

(5) Vaccine against meningococcus B (MenB).- Systematic vaccination at the age of 12 with one of the two vaccines is recommended, respecting the minimum age for each of them.Two doses.4CMenB, between 2 and 50 years old, with a minimum separation interval of 4 weeks.booster dose with 4CMenB at 12 years of age, as the meningococcal B vaccine is not interchangeable.Elective recommendation at any age in risk groups: anatomical or functional asplenia, complement factor deficiency, treatment with eculizumab or ravulizumab or sutimlimab, hematopoietic stem cell transplant recipients, HIV infection, previous episodes of AMD due to any serogroup and contacts of an index case of AMD due to serogroup B in an epidemic context.

(6) Meningococcal conjugate vaccine ACWY (MenACWY).- There are 3 MenACWY vaccines (MenACWY-TT-Pfizer, MenACWY-TT-Sanofi, and MenACWY-CRM-GSK) available to immunize children over 7 years of age. For children under 10 years of age, give one dose and then another dose starting at 10 years of age, with at least 2 months between doses.For those over 10 years old, only 1 dose of MenACWY is required, which is included in the system calendar for 11-13 years old in all communities and autonomous cities.For those who have not previously received this quadrivalent vaccine, they need to be rescued until the age of 18. For other age groups, instructions vary.It is also specifically recommended for children and adolescents residing in countries where vaccination is required in this age group, such as Canada, United States, Argentina, Brazil, Chile, Saudi Arabia, Australia, Andorra, Austria, Belgium, Cyprus, Slovakia, Greece, Ireland, Italy, Malta, Netherlands, United Kingdom, Czech Republic and Switzerland, San Marino; also for patients older than 6 weeks of age if traveling to countries with a higher prevalence of IMD due to serogroups included in the vaccine or if IMD is present Risk factors: Anatomic or functional asplenia, complement factor deficiency, treatment with eculizumab or ravulumab or sutilizumab, hematopoietic stem cell attack, IMD transplantation with previous stem cell attack, serogroup and contacts of the index case In the context of an epidemic outbreak, IMD caused by serogroups A, W or Y.

(7) Influenza vaccine .- Influenza vaccine is recommended, preferably intranasal, up to 17 years of age as a systematic recommendation and for those over 7 years of age, it is also indicated in groups at risk and their fellow residents and their contacts.If you are under 9 years old, in the first season you will receive 2 doses separated by 4 weeks;If you did not receive 2 doses in the first season, in the next season you will be given one dose if you are in a risk group.In healthy children from 6 months and even if it is the first season, one dose.If you are 9 or older you will only need one dose per season.Let's not forget that it is also indicated in pregnant adolescents, in any trimester of pregnancy, regardless of the doses previously received.

(8) SARS-CoV-2 vaccine - According to the recommendations of the Spanish Public Health Commission on vaccination against COVID-19 in the 2025-2026 season, vaccination is indicated for those who are at risk for more than 6 months or those who have received vaccinations or those who live with high-risk people and people with long-term disabilities.Antibodies that should be used are LP8.1 type of monoclonal antibodies, if there is no KP.2: Comirnaty (3 mcg [children aged 6 months to 4 years], 10 mg [children aged 5 to 11 years]) or Spikevax (0.1 mg / ml multidose 10 mg). or 5 ml 0.5 ml / 50 mg (11 years and older).First vaccination in people under 6 months of age: one dose, at least 3 months after exposure, except for those in the immune group, who receive additional doses at 3 months.First vaccination for people without a history of infection: 5 years or older, one dose 4 times 6 months Children under 3 years old, 3 doses of Comarin (3 weeks between the first and second, 8 weeks between the second and third), 3 mg, or 2 doses of Spivax (0.25 mg / 25 mg) for children under 6 years of age2 years.vaccination, the process is done with one of the new personal vaccines.Seasonal vaccination in the group at risk: regardless of the number of doses previously received, Among those who have been vaccinated or infected, one dose of vaccine or disease in 3 months.Risk groups can consult the recommendations of the Ministry of Health and the CAV-AEP vaccination guide online.

(9) Hepatitis A vaccine.- For healthy children over 7 years of age, 1 emergency dose if not previously vaccinated or ill.For pre-exposure and post-exposure risk groups, always 2 doses, 6 months apart.

(10) Measles, rubella and mumps (MMR) vaccine.- For unvaccinated people over 7 years old, 2 doses 4 weeks apart.If you have been vaccinated with a previous dose of measles (SR) vaccine, give 2 doses of MMR vaccine.If you were vaccinated with a previous dose of MMR vaccine before 11 months of age, give the second dose 10 weeks apart.less than 4 weeks from the start.If appropriate conditions exist (varicella is also required), use SRPV.

(11) Varicella vaccine (Var) - two doses at least 4 weeks apart in unvaccinated patients.12 weeks between two doses is recommended for children under 13 years of age, and 4 weeks for children over 13 years of age.

(12) Vaccination against human papillomavirus (HPV).- For both sexes, with HPV-9.For a single dose up to 25 years of age, 3 doses are required unless immunization is required (0, 2 and 6 months, at any age from 9 years).Funded to maintain single dose coverage for unvaccinated girls and boys under 18 years of age.

Advisory Committee on Vaccines and Immunizations of the Spanish Association of Pediatricians